-
公开(公告)号：US20060106218A1
公开(公告)日：2006-05-18
申请号：US11008774
申请日：2004-12-08
申请人： Andrew Pennell , James Aggen , J.J. Wright , Subhabrata Sen , Brian McMaster , Daniel Dairaghi , Wei Chen , Penglie Zhang
发明人： Andrew Pennell , James Aggen , J.J. Wright , Subhabrata Sen , Brian McMaster , Daniel Dairaghi , Wei Chen , Penglie Zhang
IPC分类号： C07D403/02
CPC分类号： C07D403/04 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/52 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/61 , C07D235/06 , C07D235/16 , C07D249/08 , C07D249/14 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04 , C07D413/12 , C07D417/04 , C07D471/04 , C07D473/34 , A61K2300/00
摘要： Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
-
公开(公告)号：US20060074121A1
公开(公告)日：2006-04-06
申请号：US11219637
申请日：2005-09-01
申请人： Wei Chen , Penglie Zhang , James Aggen , Daniel Dairaghi , Andrew Pennell , Subhabrata Sen , J.J. Wright
发明人： Wei Chen , Penglie Zhang , James Aggen , Daniel Dairaghi , Andrew Pennell , Subhabrata Sen , J.J. Wright
IPC分类号： A61K31/4162 , C07D487/02
CPC分类号： C07D471/10 , C07D487/04 , C07D487/08
摘要： Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
摘要翻译： 提供了作为CCR1，CCR2和CCR3受体中一种或多种的有效调节剂的化合物。 化合物通常是具有芳基和杂芳基组分的稠合，螺或氮杂环，并且可用于药物组合物，用于治疗CCR1，CCR2和/或CCR3介导的疾病的方法，以及用于测定中的对照 用于鉴定上述趋化因子受体的竞争性受体拮抗剂。
-
公开(公告)号：US20050256130A1
公开(公告)日：2005-11-17
申请号：US10979882
申请日：2004-11-01
申请人： Andrew Pennell , James Aggen , J.J. Wright , Subhabrata Sen , Brian McMaster , Daniel Dairaghi , Wei Chen , Penglie Zhang
发明人： Andrew Pennell , James Aggen , J.J. Wright , Subhabrata Sen , Brian McMaster , Daniel Dairaghi , Wei Chen , Penglie Zhang
IPC分类号： A61K31/496 , A61K31/506 , C07D231/12 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/04 , C07D409/04 , C07D413/14 , C07D43/14
CPC分类号： C07D409/04 , C07D231/12 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/61 , C07D235/06 , C07D249/08 , C07D249/14 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/04 , C07D471/04 , C07D473/34
摘要： Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译： 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物，并且可用于药物组合物，用于治疗CCR1介导的疾病的方法，以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号：US20050234034A1
公开(公告)日：2005-10-20
申请号：US11071880
申请日：2005-03-02
申请人： Andrew Pennell , James Aggen , J.J. Wright , Subhabrata Sen , Wei Chen , Daniel Dairaghi , Penglie Zhang
发明人： Andrew Pennell , James Aggen , J.J. Wright , Subhabrata Sen , Wei Chen , Daniel Dairaghi , Penglie Zhang
IPC分类号： A61K31/397 , A61K31/4155 , A61K31/422 , A61K31/427 , C07D403/06 , C07D487/12
CPC分类号： C07D487/04 , C07D471/10 , C07D487/08
摘要： Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
摘要翻译： 提供了作为CCR1，CCR2和CCR3受体中一种或多种的有效调节剂的化合物。 化合物通常是具有芳基和杂芳基组分的稠合，螺或氮杂环，并且可用于药物组合物，用于治疗CCR1，CCR2和/或CCR3介导的疾病的方法，以及用于测定中的对照 用于鉴定上述趋化因子受体的竞争性受体拮抗剂。
-
公开(公告)号：US20070037794A1
公开(公告)日：2007-02-15
申请号：US11486974
申请日：2006-07-14
申请人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew Pennell , John Wright
发明人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew Pennell , John Wright
IPC分类号： A61K31/55 , A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/444 , C07D417/14 , C07D413/14 , C07D403/14
CPC分类号： A61K31/444 , A61K31/437 , A61K31/4439 , A61K45/06 , C07C311/21 , C07D213/75 , C07D241/22 , C07D401/06 , C07D401/10 , C07D407/04 , C07D409/12 , C07D413/06 , C07D417/12 , C07D471/04 , C07D498/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
摘要翻译： 提供了作为CCR2受体的有效拮抗剂的化合物。 动物实验表明，这些化合物可用于治疗炎症，CCR2的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病的方法，以及用于鉴定CCR2拮抗剂的测定中的对照。
-
公开(公告)号：US20100113472A1
公开(公告)日：2010-05-06
申请号：US12611766
申请日：2009-11-03
申请人： Daniel Dairaghi , Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
发明人： Daniel Dairaghi , Lianfa Li , Andrew M.K. Pennell , Penglie Zhang
IPC分类号： A61K31/497 , A61P19/10 , A61P35/04
CPC分类号： A61K31/496
摘要： Methods are provided for the treatment of osteoporosis and multiple myeloma, using 3-imidazoyl-pyrazolo[3,4-b]pyridine compounds.
摘要翻译： 提供了使用3-咪唑基 - 吡唑并[3,4-b]吡啶化合物治疗骨质疏松症和多发性骨髓瘤的方法。
-
公开(公告)号：US20060173019A1
公开(公告)日：2006-08-03
申请号：US11332786
申请日：2006-01-13
申请人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor Charvat , Jeff Jin , Jimmie Moore , Yibin Zang , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew Pennell , John Wright
发明人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor Charvat , Jeff Jin , Jimmie Moore , Yibin Zang , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew Pennell , John Wright
IPC分类号： A61K31/496 , A61K31/4545 , C07D403/02 , C07D401/02
CPC分类号： C07C311/21 , C07D213/48 , C07D213/61 , C07D213/643 , C07D213/70 , C07D213/73 , C07D213/76 , C07D213/79 , C07D213/81 , C07D213/89 , C07D241/22 , C07D263/32 , C07D401/04 , C07D405/04 , C07D409/12 , C07D413/06 , C07D413/10 , C07D417/12 , C07D471/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
-
公开(公告)号：US20110118248A1
公开(公告)日：2011-05-19
申请号：US12309314
申请日：2009-01-13
申请人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright , Antoni Krasinski , Qiang Wang
发明人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright , Antoni Krasinski , Qiang Wang
IPC分类号： A61K31/538 , C07C311/29 , C07D213/76 , C07D401/12 , C07D401/06 , C07D413/06 , C07D405/04 , C07D471/04 , C07D417/12 , C07D498/04 , C07D401/04 , C07D413/10 , C07D401/10 , A61K31/18 , A61K31/44 , A61K31/444 , A61K31/443 , A61K31/5377 , A61K31/4375 , A61K31/4439 , A61K31/5383 , A61K31/517 , A61K31/437 , A61K31/502 , A61K31/519 , C12N5/071 , A61P9/10 , A61P9/00 , A61P25/28 , A61P29/00 , A61P3/04 , A61P3/10 , A61P13/12 , A61P1/00 , A61P11/00 , A61P37/06 , A61P35/00 , A61P25/04
CPC分类号： A61K31/5383 , A61K31/44 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4965 , A61K31/502 , A61K31/5377 , A61K31/538 , A61K45/06 , C07C311/21 , C07D213/75 , C07D241/22 , C07D401/06 , C07D401/10 , C07D407/04 , C07D409/12 , C07D413/06 , C07D417/12 , C07D471/04 , C07D498/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
摘要翻译： 提供了作为CCR2受体的有效拮抗剂的化合物。 动物实验表明，这些化合物可用于治疗炎症，CCR2的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病的方法，以及用于鉴定CCR2拮抗剂的测定中的对照。
-
公开(公告)号：US07622583B2
公开(公告)日：2009-11-24
申请号：US11486974
申请日：2006-07-14
申请人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright
发明人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright
IPC分类号： C07D471/02 , C07D237/00 , A61K31/495 , A61K31/44
CPC分类号： A61K31/444 , A61K31/437 , A61K31/4439 , A61K45/06 , C07C311/21 , C07D213/75 , C07D241/22 , C07D401/06 , C07D401/10 , C07D407/04 , C07D409/12 , C07D413/06 , C07D417/12 , C07D471/04 , C07D498/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
摘要翻译： 提供了作为CCR2受体的有效拮抗剂的化合物。 动物实验表明，这些化合物可用于治疗炎症，CCR2的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病的方法，以及用于鉴定CCR2拮抗剂的测定中的对照。
-
公开(公告)号：US08093247B2
公开(公告)日：2012-01-10
申请号：US12582001
申请日：2009-10-20
申请人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright
发明人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright
CPC分类号： A61K31/444 , A61K31/437 , A61K31/4439 , A61K45/06 , C07C311/21 , C07D213/75 , C07D241/22 , C07D401/06 , C07D401/10 , C07D407/04 , C07D409/12 , C07D413/06 , C07D417/12 , C07D471/04 , C07D498/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
摘要翻译： 提供了作为CCR2受体的有效拮抗剂的化合物。 动物实验表明，这些化合物可用于治疗炎症，CCR2的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病的方法，以及用于鉴定CCR2拮抗剂的测定中的对照。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.054 秒)
